Fengmao Biotech

Fengmao Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation targeted protein degradation (TPD) therapies, specifically molecular glues. Utilizing its proprietary GlueDiscovery platform, the company identifies and optimizes small molecules that facilitate the degradation of previously "undruggable" disease-causing proteins by recruiting E3 ubiquitin ligases. Its lead candidate, FMB-101, is a first-in-class GSPT1 degrader that received FDA IND clearance in 2023 for the treatment of advanced solid tumors and acute myeloid leukemia. Headquartered in Shanghai, the company is led by industry veteran Dr. Lin-Hua (John) Zhang and is supported by top-tier venture capital firms including Qiming Venture Partners and Lilly Asia Ventures.